Continuous Glucose Monitoring (CGM) has taken quite a dramatic turn, and now tools are given to patients with diabetes that help them manage their condition much better. Some such path-breaking companies like Dexcom set new standards for innovative approaches in diabetes care. Their latest offering is the Dexcom Stelo CGM, another step-in boundary that merges accuracy with convenience and user-friendliness regarding how diabetes is managed daily. Let’s start with what makes Dexcom Stelo a game-changer for diabetes patients and caregivers.

What is Dexcom Stelo CGM?

Stelo Glucose Biosensor System is an over-the-counter integrated Continuous Glucose Monitor intended to continuously measure, record, analyze, and display glucose values in people 18 years and older, not on insulin.
Stelo is a small biosensor worn on the back of the upper arm that harnesses Dexcom’s most accurate glucose-sensing technology. It was developed mainly to empower the 125 million Americans with Type 2 diabetes who aren’t taking insulin and those with prediabetes. With potentially powerful, tailored glucose insights straight to a smartphone that unveils how food, exercise, and sleep can impact glucose, all without painful fingersticks.

The main features of Stelo

• No fingerstick ever: This is the first over-the-counter glucose biosensor that will be marketed to diabetes patients. No fingersticks are ever needed.
• Up to 15-day wear time and waterproof: The longest-wearing biosensor on the market with the highest waterproof rating possible
• A personalized, easy-to-use app: It supplies daily, weekly, and session summary insights to help form healthier habits.
• Detects spikes and patterns: It is the first available OTC glucose biosensor to detect spikes and patterns in peoples’ blood glucose levels, helping identify meaningful glucose variability in real time so changes may be implemented for better insight.
• Proven outcomes with Dexcom glucose sensors: The application of Dexcom glucose sensors, such as Stelo CGM Dexcom, reduces A1c levels among those with Type 2 diabetes and has even been demonstrated to delay the progression of diabetes potentially. For Dexcom glucose sensors, significant changes in glucose have been reported to be associated only with those, and there are also documented reductions in measurements of cardiovascular risk for as early as three months.

Dexcom G6, G7, and Stelo: Tailored Glucose Monitoring

All products in the Dexcom portfolio are designed for those using them, making it easier for healthcare providers to get patients started on their best glucose biosensor. Dexcom G6 and Dexcom G7 are available for people with diabetes on insulin or at risk of severe hypoglycemia and are covered by commercial insurance for glucose biosensors. Both products are prescription only and covered by 97% of U.S. commercial payers, Medicare across the country, and Medicaid in many states. Stelo CGM Dexcom is designed for adults with Type 2 diabetes who do not take insulin or who have prediabetes and seek behaviour change and optimized health and also live in communities where they cannot afford glucose biosensors.

How much does Dexcom Stelo CGM cost?

The firm will sell the new FSA- and HSA-eligible glucose-monitoring device on a cash-pay model, making it accessible to anyone, regardless of their insurance status. A two-pack, or 30-day supply, of sensors, can be ordered on https://delivermymeds.com/product-category/cgm-devicess/dexcom/ for $99 or $89 monthly for an ongoing subscription, which sends two sensors every 30 days.

Will my insurance cover CGM Dexcom Stelo?

Stelo is not available through insurance yet, but when Dexcom launched the product, the company CEO, Kevin Sayer, stated he would expect this product to become one that is reimbursed by the insurance system, indicating a strong likelihood that CGM access is opening up to people with type 2 who do not have advanced diabetes.
This would be of great help to people with type 2 diabetes who want to avoid both hyperglycemia as well as hypoglycemia and who aren’t yet on insulin,” Sayer said.

Conclusion

CGM Dexcom Stelo is an essential weapon in the battle for regularity over type 2 diabetes and prediabetes, providing the individual capabilities of being under continuous glucose monitoring without necessarily relying on insulin therapy. As it reads and enables the person to understand what lifestyle elements such as diet, exercise, and stress do in real-time about glucose levels, CGM Dexcom Stelo allows the individual to take proactive steps toward a healthy life. As Dexcom expands its mission to prevent and delay the onset of diabetes, tools like Stelo CGM Dexcom, aimed specifically at those on GLP-1s and other incretins, show how tremendous the potential for optimization in treatment and slowing disease progression may be. Ultimately, empowered by data, Stelo CGM Dexcom is helping design the future of diabetes management.